Austin, United States
Lumos Pharma, founded in 1999, is a clinical-stage biopharmaceutical company headquartered in the United States. Known for their slogan, "Transforming Lives with Rare Focus", the company is dedicated to developing new therapies for rare diseases, with a primary emphasis on high-need areas where there is clear pathophysiology.
Their lead product, LUM-201, is an oral therapy aimed at treating Pediatric Growth Hormone Deficiency (PGHD). This product, currently in clinical development, aims to offer a more patient-friendly alternative to the injections required in existing treatments. Approval from the FDA could significantly shift the treatment landscape for PGHD.
With a strategic approach focused on time and cost-effective drug development, Lumos Pharma is actively pursuing partnerships to diversify their portfolio. Notably, they secured a $34.00M Series B investment in April 2016, backed by Deerfield.
Their commitment extends to acquiring or in-licensing novel treatments to address an array of rare diseases, leveraging their expertise and collaborative efforts to become a leader in providing innovative solutions.
Spero Therapeutics
